COTI-2: Targeting p53 gene mutations
Our clinical stage drug compound, COTI-2, has a major mechanism of action in human cancer cells that is dependent on p53 gene mutation status. This is important as drug treatment for p53 mutations represents a novel therapy and would be a first in class treatment for the drug company bringing COTI-2 to market.
The p53 gene is a tumor suppressing gene. It codes for a protein that inhibits the development and growth of tumors. However, if the p53 gene is mutated, cancers can develop and grow without control. Mutations of the p53 gene are the most common genetic alterations in human cancers, occurring in a wide range of cancers, including ovarian, lung, colorectal, breast, liver, bladder and other cancers.
Unlike nearly every other cancer treatment in existence today, it appears through our preclinical studies that COTI-2 is non-genotoxic. Conventional chemotherapy involves the killing of all growing and dividing cells in the body (cancer or otherwise), which often leads to significant toxic side effects in patients. By contrast, COTI-2 specifically targets and primarily destroys tumor cells.
ROSALIND: Identifying optimum treatments
ROSALIND is a smart data platform for realizing the promise of personalized medicine for cancer patients everywhere. Our proprietary programmable computer simulation of cancer cell signaling uses a gene expression and mutation profile of a patient’s tumor to evaluate a full range of available therapies.
The goal of ROSALIND is to provide better personalized treatment options based on the genetic profile of the patient’s cancer. The underlying principle behind ROSALIND is that any hope of sustained remission is dependent on therapies that restore normal cell signaling to regulate cell division and apoptosis.
ROSALIND has successfully undergone initial validation but now requires further real world testing. During this validation phase, assessments suggesting optimal personalized drug treatment options are immediately available for physicians to order free of charge. In a recent system stress test, ROSALIND evaluated 1.4 million drug combinations and provided multiple potential treatment options for patients in less than 90 minutes.
Access to high-quality cancer gene mutation profiling continues to evolve, and as we continue to advance COTI-2 in the clinic and continue with the validation of ROSALIND we believe we are working towards a brighter future in terms of patient outcomes.
If you haven't already read the article on the BBC News website, here is the link again: http://www.bbc.co.uk/news/health-36447289.